

# **Market Announcement**

17 October 2019

## Palla Pharma Limited (ASX: PAL) - Trading Halt

## **Description**

The securities of Palla Pharma Limited ('PAL') will be placed in trading halt at PAL's request, pending it releasing an announcement about the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Monday, 21 October 2019.

## Issued by

## **Cheng Tang**

Senior Adviser, Listings Compliance (Melbourne)



## **ASX ANNOUNCEMENT**

## Thursday 17th October 2019

## By E-mail

Listings Compliance Adviser ASX Limited Level 4, North Tower, Rialto 525 Collins Street Melbourne VIC 3000

Dear Sir/Madam

#### Palla Pharma Limited - request for trading halt

Palla Pharma Limited (ACN 107 872 453) (ASX:PAL) (**PAL**) requests that an immediate trading halt be granted by the Australian Securities Exchange (**ASX**) with respect to its ordinary shares in accordance with Listing Rule 17.1.

In accordance with Listing Rule 17.1, we advise that:

- the trading halt is requested pending an announcement by PAL in relation to an impending equity raising by way of a placement and accelerated non-renounceable entitlement offer:
- PAL wishes the trading halt to remain in place until the commencement of trading on Monday, 21 October 2019; and
- PAL is not aware of any reason why the trading halt should not be granted, nor is it aware of any other information required to be provided to the market or ASX in relation to the trading halt.

Should you require any other information, please do not hesitate to contact me.

Yours sincerely,

Jaime Pinto Company Secretary Palla Pharma Limited



## For more information please contact:

#### **Jarrod Ritchie**

Chief Executive Officer Palla Pharma Limited +61 3 9301 0800

#### **Brendan Middleton**

Chief Financial Officer Palla Pharma Limited +61 3 9301 0800

## **Adrian Mulcahy**

Investor Relations Market Eye +61 438 630 422 ir@pallapharma.com

### **About Palla Pharma Limited:**

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a novel water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.